Endothelin-1 (ET-1) is a major regulator of vascular function, acting via both endothelin receptor type A (ET A R) and type B (ET B R). Although the role of ET A R in vascular smooth muscle (VSM) contraction has been studied, little is known about ET B R. ET B R is a G-protein coupled receptor with a molecular mass of ~50 kDa and 442 amino acids arranged in seven transmembrane domains. Alternative splice variants of ET B R and heterodimerization and cross-talk with ET A R may affect the receptor function. ET B R has been identified in numerous blood vessels with substantial effects in the systemic, renal, pulmonary, coronary and cerebral circulation. ET B R in the endothelium mediates the release of relaxing factors such as nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factor, and could also play a role in ET-1 clearance. ET B R in VSM mediates increases in [Ca 2+ ] i , protein kinase C, mitogen-activated protein kinase and other pathways of VSM contraction and cell growth. ET-1/ET A R signaling has been associated with salt-sensitive hypertension (HTN) and pulmonary arterial hypertension (PAH), and ET A R antagonists have shown some benefits in these conditions. In search for other pathogenetic factors and more effective approaches, the role of alterations in endothelial ET B R and VSM ET B R in vascular dysfunction, and the potential benefits of modulators of ET B R in treatment of HTN and PAH are being examined. Combined ET A R/ET B R antagonists could be more efficacious in the management of conditions involving upregulation of ET A R and ET B R in VSM. Combined ET A R antagonist with ET B R agonist may need to be evaluated in conditions associated with decreased endothelial ET B R expression/activity.
INTRODUCTION
Endothelin is an endothelium-derived contracting factor and a potent vasoconstrictor [1] . Since the discovery of endothelin-1 (ET-1), great advances have been made in our understanding of the various endothelins, their production, plasma levels and clearance. Further research has enhanced our knowledge of the different endothelin receptors and their tissue and cellular distribution, signaling pathways, role in the regulation of vascular function, and dysregulation in cardiovascular disease (CVD).
The vascular effects of ET-1 are mediated by at least two receptor subtypes, endothelin receptor type A (ET A R) and type B (ET B R) [2] . Several studies have provided detailed information on ET A R, its role in vascular smooth muscle (VSM) contraction and cell growth, and its pathological role in hypertension (HTN) and other CVD [3, 4] . However, less is known about the vascular ET B R and its potential dysregulation in CVD. This commentary will discuss reports published in the PubMed database to provide insights into the role of ET B R in the regulation of vascular function and blood pressure (BP), and how alterations in its expression and signaling mechanisms could lead to HTN and other CVD. The review will briefly describe the various ET peptides, their plasma and vascular tissue levels and the pathways involved in their synthesis and metabolism. We will then address ET B R structure, subtypes, vascular tissue distribution, signaling pathways, and agonists/ antagonists. Finally, we will discuss the pathological changes in vascular ET B R in HTN and other CVD and the potential use of ET B R modulators in the management of vascular disease.
Endothelin Synthesis, Metabolism and Clearance
Endothelins include the 21-aa peptides ET-1, -2 and -3, which share structure homology with the snake venom sarafotoxin b and c (S6b, S6c). ET synthesis is initiated by preproET gene transcription and the production of long 203-aa preproETs, which are cleaved by furinlike protease to biologically inactive 37-to 41-aa big ETs. Big ETs are cleaved by ET converting enzymes (ECEs), members of the metalloprotease family, to produce active ET peptides [4] . In endothelial cells (ECs), ET-1 is stored in Weibel-Palade bodies [5] . Upon EC activation by chemical stimuli or mechanical shear stress, which increase cytosolic Ca 2+ influx [5] , these storage granules relocate from the cytoplasm to the plasma membrane and release ET-1 by exocytosis [6] . ET-1 then acts in an autocrine or paracrine fashion on ET receptors in ECs and VSMCs [4] . ET-1 is also produced by airway epithelial cells, cardiomyocytes, fibroblasts, leukocytes and mesangial cells [7] . ET synthesis is regulated mainly at the gene transcription level. PreproET-1 mRNA is upregulated during cardiovascular stress and in response to vasoactive agents such as angiotensin II (AngII) and cytokines such as tumor necrosis factor-α and transforming growth factor-β [3, 7] . Hypoxia is a major stimulus of ET-1 synthesis and signaling [8] [9] , and normobaric hypoxia stimulates preproET-1 gene expression in the rat [10] . The hypoxia-induced upregulation of ET-1 could play a role in pulmonary arterial hypertension (PAH), and the placental ischemia/hypoxia associated with preeclampsia. In ECs, preproET-1 mRNA expression increases then decreases during shear stress, and is downregulated by nitric oxide (NO), prostacyclin (PGI 2 ) and atrial natriuretic factor [7] . ECE-1 expression, and consequently ET-1 synthesis, is also regulated by protein kinase C (PKC), ets-1 transcription factor and cytokines.
The plasma levels of ET-1 are very low; 0.7 to 5 pg/mL in healthy human adults and 0.7 to 4.9 fmol/mL in Wistar rats. Tissue levels of ET-1 are also low, reaching only 120 pg/g in rat aorta. The low plasma levels of ET could be due to its continuous metabolism and clearance. In normal adults, the 24 hr urinary ET excretion is 1.7 pg/mL to 6.8 ng/mL [7] . ET clearance from the circulation is achieved by endothelial ET B Rs, also termed "clearance receptors" (Fig. 1 ) [11] and in the lung by endocytosis and degradation [12] . Following intravenous injection, ET-1 is rapidly removed from the circulation and retained primarily in the lungs, kidney and liver, and this effect is inhibited by ET B R, but not ET A R antagonists [13] . In support of ET B R-mediated clearance of ET-1, plasma ET-1 levels are increased during ET B R blockade and in transgenic ET B R-deficient rats [14] . The lungs contain the highest ET B R density as it has ~50% of the endothelium of the entire vascular tree. Considering the high blood volume in the lungs, the pulmonary endothelium acts as an efficient clearing mechanism, retaining 60% of circulating ET-1 at each pulmonary pass [12] . ET-1 clearance also takes place in the liver and kidney, and bilateral nephrectomy in rats impairs removal of exogenous ET-1 [15] .
ET B R Structure, Regulatory Domains and Active Sites
The vascular effects of ET are mediated by ET A R and ET B R [2] . A third receptor subtype with high selectivity for ET-3, termed ET C R, was characterized in the amphibian Xenopus laevis. ET A R structure and function have been extensively characterized [3, 7] , but less is known about ET B R. The human ET B R gene is located on chromosome 13 and has 7 exons and 6 introns. The ET B R is 442 aa long with a predicted molecular mass ~50kDa and 64% sequence homology with ET A R [7] . ET B R in mouse, rat, bovine, goat and pig is 441-443 aa long and displays a high degree of sequence homology with human ET B R (97% for canine, 90% for pig, 88% for mouse/rat/bovine) [16] .
ET B R belongs to the rhodopsin-type superfamily of G-protein coupled receptors (GPCR) consisting of a long extracellular N-terminus sequence, seven helical transmembrane domains (TMDs), 3 extracellular and 3 intracellular loops, and a cytoplasmic C-terminus tail (Fig. 1) . TMD I-III and VII and intervening extracellular loops constitute agonist binding. TMD IV-VI and the adjacent extracellular loops are involved in receptor binding selectivity, and the carboxyl terminal tail constitutes the signaling domain [17] . Post-translational modification of ET B R includes palmitoylation, phosphorylation and possibly glycosylation [18] . Site directed mutagenisis and [ 3 H] palmitic acid studies revealed three cysteine residues (Cys402, 403 and 405) in the carboxyl tail of human ET B R as potential palmitoylation sites [19] . The degree of C-terminal palmitoylation may affect coupling with G-proteins, the downstream signaling pathways, and the ET B R phosphorylation pattern. Studies have identified 13 phosphorylation sites [18] , mainly at the end of the C-terminus (435-442 aa) (Fig. 1) . ET B R phosphorylation may affect receptor function, and phosphorylation in the third cytoplasmic loop and/or C-terminal tail by GPCR kinases (GRKs) or β-arrestins may be involved in receptor desensitization [20] . ET B R contains a glycosylation site at Asn59, but does not appear to affect ligand binding.
The canonical ET B R was cloned from human liver and placental cDNA libraries. Several alternative splice variants of human ET B R have been identified. The first splice variant has an additional 10 aa at the second cytoplasmic loop of ET B R, but has similar binding and functional characteristics as wild-type ET B R [21] . A second splice variant from human placental libraries has 436 aa residues and differs from wild-type ET B R in the last 52 aa of the carboxyl terminal. Although this splice variant has the same binding properties as wildtype ET B R, it lacks functional coupling to phosphoinositide turnover [22] . A third splice variant in human melonama cell line has its transcription initiation 939bp upstream from wild-type ET B R, an additional ~90 aa at the N-terminus and a shorter 3′ untranslated region, but exhibits similar binding and functional characteristics as wild-type ET B R [23] .
ET B R Binding to ET-1 and Receptor Trafficking
ET receptors bind ET-1 with high affinity. ET-1 binds polyvalently to ET A R and both ET A R antagonists and endogenous physiological antagonists allosterically reduce ET A R function. In rat mesenteric resistance arteries, ET-1 binds tightly to ET A R and causes long-lasting contraction (> 20 min) that is only partly and reversibly relaxed by the ET A R antagonists BQ123 and SB234551. Because of the tight binding of ET-1 to ET A R, research has been directed to the agonist residence time on the receptor and the rate of dissociation of the agonist-receptor complex. The neuropeptide calcitonin-gene-related peptide and its receptor can act as a physiological endogenous indirect negative allosteric modulator of ET A R, suggesting that cross-talk between peptidergic GPCRs could reduce the affinity and increase the rate of dissociation of the ET-1/ET A R complex [24] .
ET B R differs from ET A R in its binding affinity to ET-1, and this may ultimately affect the fate of the receptor and ET-1. Both ET A R and ET B R are rapidly internalized upon agonist stimulation, a process that involves GRK, arrestin, dynamin and clathrin. Internalized ET A R and ET B R are directed to Rab5 positive early endosomes (sorting endosomes), then targeted to different intracellular fates. ET A R is directed to the pericentriolar compartment for recycling, and subsequently reappears back at the plasma membrane in a ligand-unbound state [25] . Ligand-bound ET B R is internalized, but, unlike ET A R, it is sorted to the late endosomes/lysosomes for degradation; a major pathway for ET-1 "clearance" [26] . Bioinformatics and mutation analyses suggest that recycling of ET A R is mediated by 390-406 aa within the internal postsynaptic density 95/disc-large/zona (PDZ) ligand-binding peptide motif in the C-terminal tail. This motif is lacking in the C-terminal region of ET B R, providing a mechanism for the divergent endocytotic sorting of ET A R vs. ET B R [27] . Studies have shown that ET B Rs are more readily accessible to circulating ET-1 than ET A Rs likely because ET B Rs outnumber ET A Rs or due to the close proximity of the ET B R pool on ECs, resulting in greater changes in circulating ET-1 levels during blockade of ET B R as compared to ET A R [28] .
ET A R and ET B R Dimerization
ET A R and ET B R may form homodimers or heterodimers or higher order oligomers that may modify ligand binding, receptor activation, desensitization and transmembrane signaling. ET A R and ET B R traffic to the cell surface first as monomers then as constitutive heterodimers. Formation of ET B R/ET A R heterodimers is supported by the observation that ET-1 is a bivalent ligand that can bridge between the two receptor subtypes in the plasma membrane [29] . ET B R internalizes more slowly when present as ET A R/ET B R heterodimer, and the heterodimer dissociates after prolonged exposure to ET B R agonist and subsequent internalization and endocytosis, whereas homodimers are resistant to ligand-induced dissociation [29] . Both selective ET A R and ET B R antagonists may be required to inhibit the function of heterodimeric receptor. Cross-talk between ET A R and ET B R has been suggested [30] . Binding studies have shown that ET A R and ET B R activation of intracellular signaling pathways may influence ET-1 binding to its receptor subtypes. However, whether these binding properties would translate into functional ET A R/ET B R cross-talk has not been fully tested [31] . In an in situ cranial window of the rat basilar artery, ET-1 caused contraction that was relaxed by 50% by the ET A R antagonist BQ123, and the remaining 50% of ET-1 contraction was relaxed by the ET B R antagonist BQ788, suggesting an ET B R-mediated component of contraction. BQ788 in the absence of BQ123 did not cause relaxation, and subsequent addition of BQ123 completely relaxed the ET-1 contraction. Also, PD145065, a mixed ET A R/ET B R antagonist, completely relaxed ET-1 contraction both in the absence and presence of BQ123. The ability of ET A R antagonist to completely relax ET-1 contraction only in the presence of ET B R antagonist, and vice-a-versa, suggests cross-talk between ET A R and ET B R in the cerebral circulation [32] . ET B R may form heterodimers with other receptors such as the dopamine D3 receptor and angiotensin type 1 receptor (AT 1 R) in the renal proximal tubules [28] [33] [34] [35] , and the receptor heterodimerization may play a role in salt and water homeostasis and BP control.
ET B R Tissue and Subcellular Distribution
ET B R predominates in ECs and is present in low densities in VSMCs of some vascular beds such as the aorta, coronary arteries, mesenteric arteries and veins of experimental animals and in human mammary artery (Table 1 ) [7] . ET B R is also expressed in vascular adventitial fibroblasts [36] , the myocardium, renal tubules, airway smooth muscle, hepatocytes, osteoblasts, central and peripheral neurons, endocrine tissues and reproductive tract. ET A R is expressed in VSMCs, vascular adventitial fibroblasts [36] , airway smooth muscle, cardiomyocytes, liver stellate cells, neurons, osteoblasts, melanocytes, keratinocytes, adipocytes and the reproductive system [7] .
Studies have examined the subcellular distribution of ET A R and ET B R in various cardiovascular cell types including human cardiac and endocardial cells, and aortic VSMCs and ECs. Both ET A R and ET B R appear in the plasma membrane, cytosol and the nucleus including the nuclear envelope membrane, but only ET B R appears in the nucleoplasm [37] ( Table 1) . Whether the differences in the cellular and subcellular distribution of ET receptor subtypes play a role in the different efficacy of ET receptor antagonists in pulmonary arterial disease as compared to other systemic vascular and cardiac disease remains to be examined.
Endothelial ET B R Signaling. NO, PGI 2 , EDHF
Depending on the effector cell type, two ET B R subtypes have been suggested, vasodilator ET B R in ECs and vasoconstrictor ET B R in VSMCs [38] . In ECs, ET B R is coupled to signaling pathways that increase the release of relaxing factors such as NO (Fig. 2) . In rat aorta, the ET B R agonist IRL-1620 binds to endothelial ET B R and causes an increase in [Ca 2+ ] i which activates NO synthase to produce NO. NO diffuses into VSMCs, where it stimulates soluble guanylate cyclase to produce cGMP and induce vascular relaxation. NO and NO donors inhibit ET-1 release or counteract its vasoconstrictor effects in VSM, and in vivo administration of the NOS inhibitor N ω -nitro-L-arginine methyl ester (L-NAME) enhances ET-1 release from ECs. ET B R mediates the release of other endothelium-derived vasodilators such as PGI 2 and endothelium-derived hyperpolarizing factor (EDHF) [7] (Fig.  2) . In endothelium-intact rat carotid artery, IRL-1620 causes relaxation that is not abolished by L-NAME or the cyclooxygenase (COX) inhibitor indomethacin, but abolished by tetraethylammonium, a nonselective K + channel blocker, supporting an EDHF component of ET B [42] . The ET A R or ET B Rmediated increase in Ca 2+ binds calmodulin to form a complex, which activates myosin light chain (MLC) kinase and leads to MLC phosphorylation, actin-myosin interaction and VSM contraction [7] .
ET A R and ET B R may activate other types of Ca 2+ channels and other mechanisms of VSM contraction. When compared with ET-1 and ET-2, ET-3 causes little change in [Ca 2+ ] i in rat preglomerular VSMCs. Also, while ET-1 and S6c decrease renal blood flow, in preglomerular VSMCs ET-1 produces a typical biphasic [Ca 2+ ] i response that is not abolished by diltiazem, while S6c has no effect [43] , suggesting that ET-1 induced Ca 2+ influx involves channels other than voltage-gated Ca 2+ channels such as receptor-operated (ROCCs) and store-operated Ca 2+ channels (SOCCs) and that ET B R-mediated preglomerular constriction may involve a Ca 2+ -independent mechanism. ET-1 induced VSM contraction and MLC phosphorylation could involve ET A R or ET B R-mediated G 12 -coupled activation of reverse mode Na + /Ca 2+ , and G 13 -coupled Rho-kinase dependent inhibition of MLC phosphatase. Also, ET A R/ET B R-mediated increase in DAG stimulates PKC [7] , and ET B R may mediate inhibition of MLC phosphatase via PKC-dependent phosphorylation of CPI-17 [44] . In rat cerebral artery, the PKC inhibitor Ro-31-8220 attenuates S6c-induced contraction and ET B R expression [45] . Mitogen-activated protein kinase (MAPK) is an important mediator of ET B R transcription. In rat mesenteric artery in organ culture, the Raf inhibitor SB386023b, acting upstream from MEK/ERK 1/2 , and the MEK inhibitor PD98059 cause a decrease in ET B R mRNA levels [46] . Also, in porcine coronary artery in organ culture, S6c causes contraction and increases ET B R mRNA and protein levels that are inhibited by the PKC inhibitor bisindolylmaleimide or Ro-32-0432, the MEK inhibitor PD98059, and the C-jun terminal kinase (JNK) inhibitor SP600125, supporting that PKC and MAPK are involved in the regulation of ET B R expression/activity [47] . Also, Ca 2+ / calmodulin-dependent protein kinase II (CAMK-II) may interact with the ERK 1/2 pathway to enhance ET B R expression in rat cerebral artery. In human VSMCs, the ET A R antagonist BQ123, but not ET B R antagonist BQ788, inhibits ET-1 induced activation of ERK 1/2 , and S6c causes only slight and transient activation of ERK 1/2 , suggesting a predominant role of ET A R, and highlighting the diverse signaling cascades in different vascular beds from different species. Other ET A R/ET B R-mediated signaling pathways include phospholipase D with generation of DAG, phospholipase A 2 with release of arachidonic acid, the Na + /H + exchanger, Src-family tyrosine kinases, phosphatidylinositol 3-kinase (PI 3 K) and p38 MAPK [3] . For instance, in Chinese hamster ovary (CHO) cells expressing recombinant human ET B R, ET-1 causes sustained [Ca 2+ ] i influx that involves G (q/11) /PLC-independent, but p38 MAPK-dependent activation of the Na + /H + exchanger [48] .
ET B R Agonists and Antagonists
ET A R has subnanomolar affinity for ET-1 and ET-2 and lower affinity for ET-3 (ET-1=ET-2≫ET-3) (Fig. 3) . ET B R binds with the same affinity for ET-1=ET-2=ET-3 as well as S6b and S6c [7] . S6b does not discriminate between ET A R and ET B R, but S6c is highly selective for ET B R. Other ET B R agonists include the synthetic linear analogs BQ3020 and IRL-1620. [Ala1, 3, 11, 15] ET-1 is a linear analog of ET-1 in which the disulfide bridges are removed by substitution of Ala for Cys residues, and is a selective ET B R agonist. IRL-1620 is highly specific as compared with S6c, which may stimulate receptors other than ET B R [38] . ET B R antagonists include BQ788, IRL-1038, IRL-2500 and RES-701. Non-peptide ET B R antagonists include A-192621 and Ro46-8443 (Table 1) .
ET A R-ET B R Balance
Under physiological conditions, the vasodilator effects of endothelial ET B R oppose the vasoconstrictor and mitogenic effects of ET A R and possibly ET B R in VSMCs, thus creating a fine balance between ET A R-and ET B R-mediated effects in the circulation. In pathological conditions, there could be not only upregulation of ET A R, but also downregulation of endothelial ET B R and its vasodilator effects thus promoting the vasoconstrictior and mitogenic effects of ET-1 in VSM via activation of ET A R and possibly ET B R. Also, because of the ET B R clearance properties, disruption of functional ET B R may reduce ET-1 clearance and increase its levels in the circulation, thus allowing more ET-1 to activate ET A R, and resulting in further amplification of its vasoconstrictor and VSM hypertrophic effects. Studies with ET B R transgenic and knockout (KO) animals as well as some clinical studies have provided insights into the vascular protective role of ET B R, and suggested that dysregulation of ET B R could be associated with certain disorders such as Hirschsprung's disease and CVD such as HTN, coronary artery disease (CAD), cerebral ischemia and atherosclerosis.
ET B R-Deficient Phenotypes
Mutations in EDNRB gene have been linked to Hirschsprung's disease in humans, a congenital disease characterized by aganglionic megacolon, absence of enteric ganglia and lack of innervation to the lower gastrointestinal tract. The disease is associated with polymorphism and several missense mutations in EDNRB gene that lead to decreased expression, changes in cell signaling, and loss of ET B R function [49] . Splice variants of the EDNRB gene from patients with Hirschsprung's disease that are lacking 134 bp of exon 5 and others containing the substitution A950G in exon 4 of EDNRB have been associated with loss of ET B R function. Other mutations of Hirschsprung's disease include F29L, G57S, A183G, W276C, A305N, R319W, M374I and P383L [49] . Mutation of Ser390 by L-Arg at the origin of the C-terminal tail of ET B R reduces the capacity to increase [Ca 2+ ] i and adenylyl cyclase, but does not affect receptor binding [50] . Substitution of the highly conserved Asp147 by Ala at TMD II and Try276 by Cys in TMD V affects G q and PLC signaling, and reduces Ca 2+ mobilization without affecting ligand binding [51] (Fig. 1 ). The human phenotype may also have mutations in the ET-3 gene [49] and Waardenburg Syndrome type 4A, a genetic disorder associated with deafness, neural crest and pigmentation anomalies traceable to at least six genes that include ET-3 and EDNRB genes, supporting the importance of ET-3/ET B R signaling.
Certain mouse and rat strains such as piebald mice (s), piebald-lethal (sl) mice, and spottinglethal (sl) rats exhibit striking similarities to the human condition, and have a naturally occurring mutation of EDNRB gene that produce a phenotype with aganglionic megacolon and developmental defects in neural crest cell migration and differentiation. Piebald (s) mice exhibit a natural spontaneous mutation in EDNRB gene with a 5.5-kb retroposon-like element in intron 1 that causes premature termination and aberrant splicing of ~75% of the normally initiated EDNRB transcript, resulting in ~25% reduced EDNRB levels and partial loss-of-function [52] . These mice exhibit reduced white spotting of their coat by ~20% but do not manifest megacolon. Piebald-lethal (sl) mice exhibit a natural deletion mutation of the entire EDNRB gene, identical to that of homozygous EDNRB −/− KO mouse, resulting in a phenotype of white-spotted coat, aganglionic megacolon and juvenile death at 2-4 week of age [53] . Heterozygous ET B R-deficient mice have been generated by crossing inbred mice heterozygous for targeted disruption of the EDNRB gene with mice homozygous for the piebald (s) mutation of the EDNRB gene. Heterozygous ET B R +/− mice display increased BP that can be reversed by the ET A R antagonist BQ123 but not the ET B R antagonist BQ788, and elevated plasma ET-1 levels likely due to impaired clearance via ET B R [54] . Other groups have produced a viable ET B R-deficient mouse by genetic rescue of the lethal ET B R KO mice by breeding with mice harboring a dopamine-β-hydroxylase ET B R transgene in the enteric nervous system. The 'rescued' ET B R-deficient mice do not have megacolon, but develop salt-sensitive HTN, and impaired endothelial function independent of high salt (HS) diet or HTN, suggesting that in this model salt-sensitive HTN is not mediated by endothelial dysfunction [55] . Interestingly, EC-specific ET B R KO mice, generated by using a Cre-loxP approach, have aortic endothelial dysfunction, decreased release of NO and increased plasma ET-1 levels, suggesting that endothelial ET B R mediates a tonic vasodilator effect and possibly clearance of ET-1. However, in contrast to models of total ET B R ablation, ECspecific ET B R KO mice do not develop salt-sensitive HTN, suggesting that non-EC ET B R is important for BP regulation [56] .
Spotting lethal (sl) rats have a naturally occurring mutant EDNRB gene with a 301-bp deletion between exon 1 and intron 1 including the last 265 bp from exon 1, leading to aberrant splicing of mRNA, missing coding sequence for TMD-I and -II of ET B R, and juvenile death. Transgenic rescue of the intestinal phenotype in the (sl) rat has been developed by harboring a wild-type rat ET B R cDNA, whose expression is driven by the human dopamine-β-hydroxylase promoter. Transgenic ET B R-deficient rats do not express ET B R driven by the endogenous promoter, but express dopamine-β-hydroxylase-driven ET B R in adrenergic tissues such as the adrenal medulla and sympathetic ganglia and therefore exhibit normal enteric nervous system development and normal BP, but become severely hypertensive when placed on HS diet [14] (Table 2) .
ET B R and Regulation of the Systemic Circulation
ET B R plays an important role in the systemic circulation. Infusion of ET-1 or IRL-1620 in Sprague-Dawley rat elicits a biphasic BP response consisting of a fast onset and transient depressor effect (10 to 45 sec) likely due to activation of endothelial ET B R, followed by a prolonged pressor response (3 to 4 min) due to activation of ET A R and possibly ET B R in VSM ( Table 3 ). The pressor response to IRL-1620 is much smaller than that of ET-1. ET-1 or IRL-1620 also increases total vascular resistance, reduces cardiac output, and causes mesenteric and renal vasoconstriction [57] . Administration of the ET A R antagonist BQ123 or FR-139317 enhances the initial depressor effect of ET-1 and reduces the pressor effect, supporting ET B R-mediated depressor effects. However, the pressor and regional constrictor effect of ET-1 are only inhibited by 25-50% even with high doses of ET A R antagonists, suggesting a vasoconstrictor role for ET B R [58] . In the conscious rat, administration of the ET B R antagonist BQ788 does not reduce the pressor response induced by ET-1, but rather accelerates its onset and potentiates the increase in total vascular resistance, suggesting a predominant role of endothelial ET B R in limiting the pressor effects of ET-1 [59] . On the other hand, the ET B R agonist S6c is a potent pressor agent in the pithed rat [60] , causing a transient decrease in BP followed by a long-lasting pressor response and marked renal and mesenteric vasoconstriction. Also, the ET B R antagonist Ro-468443 causes reduction in BP in anaesthetized normotensive rats, providing in vivo evidence for VSM ET B R-mediated vasoconstriction [61] .
In the anesthetized rabbit, infusion of the ET A R antagonist BQ123 markedly reduces the pressor response to both ET-1 and big ET-1. In contrast, infusion of the ET B R antagonist BQ788 potentiates ET-1 or big ET-1-induced pressor effects, supporting that blockade of endothelial ET B R-mediated vasodilation would enhance the systemic vasoconstrictor and pressor effects of ET-1 acting through ET A R. BQ788 also increases the plasma levels of ET-1 and big ET-1, suggesting that ET B R blockade could displace ET-1 from clearance ET B R thus allowing more ET-1 to activate ET A R [62] .
In healthy men, 15 min infusion of BQ788 in the left antecubital vein had no effect on mean arterial pressure (MAP), but caused systemic vasoconstriction, suggesting a role of endothelial ET B R in promoting systemic vasodilation likely through the release of NO and other vascular relaxing factors [63] . In contrast, infusion of BQ123 in the brachial artery for 60 min caused a dose-dependent decrease in systemic vascular resistance and MAP in healthy men [64] , indicating that ET A Rmediated vascular tone contributes to the maintenance of basal systemic vascular resistance and MAP, although ET A R blockade with BQ123 could also shift ET-1 to activate endothelial ET B R and promote further vasodilation.
Taken together these findings highlight the importance of endothelial ET B R in reducing the systemic pressor effects of ET-1 and MAP partly by opposing the vasoconstrictor actions of ET A R, and partly by enhancing ET-1 clearance from the circulation and suppressing the amount of ET-1 available for ET A R to promote vasoconstriction.
Effects of ET B R in Systemic Arteries and Veins
ET B R mediates significant vascular effects ranging from vasodilation to vasoconstriction depending on the arterial or venous bed studied. In vitro studies on rat mesenteric arteries mounted on wire or perfusion myographs have shown that the ET B R agonists ET-3 and S6c produce small constrictor effects [3] [4] . The expression and contractile effects of ET B R appear to change in blood vessels in organ culture. In one study on freshly isolated rat mesenteric artery, ET-1 and ET-3 induced strong contractions, with ET-1 being 20-fold more potent likely due to ET A R stimulation. In contrast, neither S6c nor IRL-1620 induced contraction likely because any VSM ET B R-mediated vascular contraction was offset by endothelial ET B R-mediated vascular relaxation. However, in mesenteric artery segments cultured for 24 hr, ET-3 is only 3-fold less potent than ET-1, and S6c and IRL-1620 induce contractions that are ~60% of ET-1 induced contraction, likely due to upregulation of VSM ET B R. Removal of the endothelium has no effect on S6c-induced contraction, suggesting that the appearance of ET B R-mediated contraction following organ culture may not involve downregulation of endothelial ET B R or endothelium-derived vasodilators [65] . The upregulation of ET B R expression and S6c-induced ET B R-mediated contraction in organ culture may involve de novo transcription of the receptor, and activation of PKC, ERK 1/2 MAPK and NF-κB dependent mechanisms [66] . Other studies have shown that increased perfusion pressure in isolated rat mesenteric arteries results in increased ET B R mRNA expression and protein [67] , and periodic stretch increases ET B R mRNA levels up to 10-fold in rat aortic VSMCs [68] .
In human brachial artery, infusion of BQ123 caused forearm vasodilatation that was attenuated by 95% during an NO clamp by L-NMMA infusion, but not during inhibition of prostanoid generation. Co-infusion of BQ788 with BQ123 attenuated the vasodilatory response by 38%, supporting a role of endothelial ET B R [69] . On the other hand, localized infusion of S6c causes constriction in human forearm resistance arteries and dorsal hand veins [70] . In human internal mammary artery precontracted with ET-1, both the ET A R antagonist BQ123 and ET B R antagonist BQ788 cause relaxation, suggesting a role of both ET A R and VSM ET B R in ET-1 induced contraction [71] . Other in vitro studies in human coronary artery and mammary artery have shown little vasoconstrictor effects of the ET B R agonists S6c, BQ3020 and [Ala1,3,11,15]-ET-1 [16] .
Evidence also suggests a role of ET B R in the venous circulation. Veins may have vasodilator ET B R in ECs. In rat vena cava precontracted with PGF2α, S6c elicits marked relaxation both in the absence and presence of L-NAME, suggesting that both NO and EDHF pathways may be involved [72] . On the other hand, in human saphenous vein [73] , rabbit saphenous vein [74] , and rat mesenteric vein [75] and vena cava [76] , S6c causes contraction suggesting VSM ET B R-mediated venoconstriction. Thus, stimulation of ET B R in the endothelium or VSM of systemic arteries and veins can cause vasodilator or vasoconstrictor effects, respectively, and dysregulation of ET B R in different cell types and vascular beds may play a role in vascular disease.
Dysregulation of ET-1 and Vascular ET B R in Hypertension
The prominent and prolonged vasoconstrictor effects of ET-1 have suggested a role in HTN. However, most patients with HTN show normal or slightly increased ET-1 levels [77] . Among African-Americans, plasma ET levels are greater in hypertensive than normotensive controls, but among individuals with similar severity of HTN plasma ET levels are not higher in African-Americans than Caucasians [77] . Upregulation of the ET system is commonly observed in severe cases of HTN associated with heart failure, CAD, atherosclerosis and PAH. For example, plasma levels of ET-1 and big ET-1 are markedly elevated in patients with heart failure compared with control subjects [78] . The discrepancy in plasma ET-1 levels among hypertensive patients may be related to its rapid clearance from the blood stream. Also, ET-1 is mainly secreted in a polarized fashion from ECs to the underlying VSMCs, leading to minimal increases in circulating plasma ET-1. ET-1 tissue expression is increased in some forms of human HTN including salt-sensitive HTN, low renin HTN, and obesity and insulin resistance-related HTN [77] . Also, the 24 hr urinary excretion of ET-1 is greater in hypertensive patients with heart failure (17.0 ng/g urinary creatinine, UC) than control subjects (1.7 ng/g UC) [7] .
ET-1 may also play a role in animal models of HTN such as deoxycorticosterone acetate (DOCA)-salt hypertensive rat [28] [77] . ET-1 levels are greater in the aorta of DOCA-salt hypertensive rats (730 pg/g) than control rats (120 pg/g) [79] . ET-1 levels are also increased in the vascular wall of DOCA-salt-treated spontaneously hypertensive rats (SHR), saltloaded stroke-prone SHR, Dahl salt-sensitive rats, AngII-infused rats and 1-kidney 1-clip Goldblatt hypertensive rats, but not in SHR, 2-kidney 1-clip hypertensive rats or L-NAMEtreated rats [77] .
Decreased endothelial ET B R may play a role in HTN. Chronic treatment of Sprague-Dawley rats with the ET B R antagonist A-192621 is associated with increased BP, enhanced aortic contraction, and reduced endothelium-dependent aortic relaxation and NO production [80] . The vasoconstrictive effects of A-192621 are greater in rats on HS diet than normal salt diet, suggesting that endothelial ET B R may influence basal vascular tone by activating the NOcGMP pathway, a protective effect that is enhanced during HS diet [80] . Also, in hamsters, infusion of low dose of A-192621 did not cause pressor effects, but markedly reduced the transient hypotensive phase induced by intravenously injected ET B R agonist IRL-1620. A-192621 alone or with the selective ET A R antagonist atrasentan potentiated the pressor response to exogenous ET-1. Also, infusion of high dose of A-192621 for 16 days increased BP and plasma ET-1 levels. These findings are consistent with a role of endothelial ET B R in the vasodilatory response to ET-1 and in clearance of endogenous ET-1, and therefore blockade of ET B R potentiates ET A R-mediated increase in vascular resistance and BP [81] .
Role of ET B R in Renal Circulation and Sodium and Water Homeostasis
ET B R plays a role in the regulation of renal blood flow and the sodium and water balance. In situ studies in superfused kidney and afferent arterioles of Sprague-Dawley rats on HS diet (8%) showed increased relaxation to big ET-1, ET-1 and S6c, when compared to rats on normal salt diet (0.66%) [28] . Blockade of ET B R with A-192621 abrogated the vasodilatory response to ET-1 during HS diet. Also, ET B R expression in preglomerular microvessels was increased during HS, whereas ET A R expression was unchanged, suggesting that the reduced vasoconstrictor response of afferent arterioles to ET peptides during HS diet is likely due to vasodilator actions of endothelial ET B R [28] .
ET A R and ET B R may contribute differently to the ET-1 response in afferent and efferent arterioles. In afferent arterioles, ET-1 induced similar constriction in ET B R-deficient and wild-type mice, the ET A R antagonist BQ123 inhibited this response in both groups, and the ET B R agonists [Ala1, 3, 11, 15] ET-1 and IRL-1620 had no effect on arteriolar diameter. In efferent arterioles, ET-1 caused stronger constriction in wild-type than ET B R-deficient mice, BQ123 abolished constriction only in ET B R-deficient mice, and [Ala1, 3, 11, 15] ET-1 and IRL-1620 constricted only arterioles of wild-type mice. L-NAME decreased basal diameter in wild-type but not ET B R-deficient mice, supporting contribution of ET B R to basal NO release in efferent arterioles. Thus in afferent arterioles ET A R mediates vasoconstriction and ET B R has no vasoconstrictor or vasodilator action, while in efferent arterioles both ET A R and ET B R in VSM mediate vasoconstriction, and endothelial ET B R mediates vasodilatation [82] , highlighting the differences in ET A R and ET B R regulation in different renal arterioles.
The renal medullary ET-1 system and ET B R play a role in the control of sodium and water excretion and BP [28] [83] . ET B R is abundant in the epithelium of the collecting ducts of the renal medulla, and is considered the main inhibitory site of ET-1 action on sodium and water reabsorption. ET B R activation increases renal medullary blood flow by increasing NO, vasodilator cyclooxygenase metabolites, and possibly cytochrome p-450 products such as 20-HETE [84] , which sodium excretion.
In support of a role of ET B R in sodium and fluid homeostasis, blockade of ET B R or genetic ET B R deficiency in rats or mice leads to salt-sensitive HTN [14, 80, 85] . Also, renal collecting duct-specific KO of ET B R in mice is associated with HTN, supporting an antihypertensive role of ET B R by enhancing sodium and water excretion [86] . Interestingly, the renal medullary production of 20-HETE, appears to involve ET B R, and to be enhanced during HS diet. This is supported by the observation that blockade of ET B R in the rat renal medulla during high dietary salt intake results in decreased renal medullary 20-HETE production and salt-sensitive HTN [84] .
ET B R may also be cardio-and renoprotective in HTN, and DOCA-salt-induced cardiovascular and renal dysfunction deteriorates following treatment with an ET B R antagonist. The protective role of ET B R against HTN may also be related to its effects on oxidative stress. Activation of clearance ET B R could decrease the amount of ET-1 available to activate ET A R and stimulate oxidative stress. Studies have shown an increase in BP and oxidative stress in ET B R-deficient rats on HS diet, and ET A R blockade prevents these effects, supporting a link between ET B R deficiency and ET A R-mediated increase in reactive oxygen species [87] . ET-1 stimulates superoxide production in the vasculature and may contribute to the increased oxidative stress and BP in salt-sensitive HTN, and the elevated BP during ET B R blockade or infusion of ET-1 is attenuated by antioxidants. Also, the superoxide dismutase mimetic tempol attenuates the development of HTN in the initial days of rat treatment with an ET B R antagonist, supporting that superoxide contributes to the increased BP during ET B R deficiency and HS diet [87] .
Modulators of Endothelin Receptors in HTN
Chronic treatment with the ET A R/ET B R antagonist bosentan or the ET A R antagonist ABT-627 attenuates HTN and vascular remodeling in DOCA-salt rats, suggesting that ET A R plays a major role in salt-sensitive HTN [88] . The net benefit of ET receptor antagonists in HTN could depend on their effectiveness to suppress the vasoconstrictive and growth promoting effects of ET. For instance, in hypertensive rats overexpressing ET-1, selective ET A R antagonists slightly lower BP, but markedly attenuate vascular hypertrophy, particularly in resistance arteries. Similarly, treatment of SHR and DOCA-salt hypertensive rats with bosentan reduces BP, but abolishes the vascular hypertrophy and remodeling of resistance arteries beyond what could be explained by the BP lowering effect [77] . In healthy subjects, ET A R antagonists alone or in combination with ET B R antagonists do not modify basal vascular tone, while in essential hypertensive patients ET A R blockade causes a slight vasodilation that is potentiated by ET B R blockade. In line with a pathological role of ET-1 in essential HTN, bosentan lowers BP in patients with essential HTN. TAK-044 (ET A R/ET B R antagonist) and sitaxsentan (selective ET A R antagonist) have shown some benefits in HTN, and the ET A R antagonist darusentan has shown promising results in patients with resistant HTN [77] . However, sitaxsentan has recently been removed from the market by the manufacturer. Also, the more recent DORADO and DORADO-AC phase III large clinical trials evaluating darusentan for treatment of resistance HTN, failed to achieve the co-primary efficacy endpoint of changes in trough sitting systolic and diastolic BP from baseline to week 14 [89] . Although the study was 95% powered to detect an 8 mmHg improvement in systolic and diastolic BP, reductions in mean trough sitting systolic and diastolic BP were not statistically different between darusentan and placebo groups, and therefore, the use of darusentan has been terminated for the treatment of resistance HTN [89] .
One of the common side effects of mixed ET A R/ET B R antagonists or selective ET A Rantagonists is hemodilution, fluid retention and edema [83] [90] . Blockade of renal ET B R and probably ET A R may reduce sodium excretion, and the resulting fluid retention may explain the failed clinical trials of ET receptor antagonists in the treatment of cardiac failure. The lack of efficacy of ET receptor antagonists against HTN in human trials suggest that the animal studies may not translate well in the clinical setting. However, larger clinical trials may be needed to determine any potential benefits of modulators of the ET system in HTN. ET receptor antagonists may not only decrease BP in HTN, but could also, on the long-term, prevent target organ damage and other cardiovascular complications associated with HTN such as PAH, CAD, restenosis after angioplasty, and atherosclerosis [77] .
ET B R in Pulmonary Circulation and Dysregulation in Pulmonary Hypertension
ET-1 plays an important role in the pulmonary circulation. In isolated rat intrapulmonary arteries ET-1 induced marked contraction, and bosentan, a dual ET A R/ET B R antagonist, and ambrisentan, an ET A R antagonist with >4000-fold higher selectivity over ET B R, relaxed ET-1 induced contractions by 30%, and 26%, respectively. Combination of the phosphodiesterase inhibitor tadalafil with bosentan relaxed ET-1-contracted arterial rings by 53%, and a combination of tadalafil with ambrisentan acted synergistically to relax arterial rings by 83%. Endothelium removal abolished the vasodilator response to tadalafil and its synergistic vasorelaxant effect with ambrisentan. Also, in the presence of the selective ET B R antagonist BQ-788 the vasorelaxant effects of ambrisentan and tadalafil were additive but not synergistic. These data suggest that ambrisentan and tadalafil synergistically inhibit ET-1-induced constriction of rat intrapulmonary arteries and that endothelial ET B R is necessary to enable a synergistic vasorelaxant effect of the drug combination [91] . Also, blockade of ET B R induces vasoconstriction in perfused rat lung [92] and in rat and rabbit pulmonary artery [93] , likely due to reduced vasodilator effects of endothelial ET B R as well as inhibition of ET B R-mediated ET-1 clearance and thereby enhancement of ET-1/ET A R activity. On the other hand, in perfused rat lung, ET-1 induces pulmonary vasoconstriction that is inhibited by ET A R/ET B R blockade (BQ123+BQ788) more effectively than BQ123 alone, suggesting that both ET A R and likely VSM ET B R mediate ET-1 contraction [92] . Also, the mitogenic effects of ET-1 in pulmonary VSMCs appear to involve both ET A R and ET B R [94] .
The ET-1 system appears to be upregulated during hypoxia. ET-1 levels are increased in the lungs of patients with pulmonary hypertension (PH) [95] . Also, the levels of preproET-1 and ET-1 peptide and ET A R and ET B R mRNA and protein are increased in the chronically hypoxic, hypertensive rat lung [10] . ET B R is also important in the regulation of pulmonary vascular tone in response to hypoxia, and alterations in ET B R activity may lead to increased pulmonary vasoconstriction, vascular remodeling and PAH. Chronic hypoxia augments ET B R-mediated vasodilation in isolated perfused rat lungs [96] . Deficiency of pulmonary vascular ET B R predisposes to the development of PH. The ET B R antagonist BQ788 exacerbates hypoxia-induced pulmonary vasoconstriction in rats and causes PH and vascular remodeling in the ovine fetus [97] . Also, ET B R-deficient rats develop PH and exaggerated pulmonary vasoconstriction when exposed to acute hypoxia or ET-1 stimulation. Transgenic sl/sl rats lack ET B R mRNA expression in the pulmonary vasculature and develop PH, increased right ventricular hypertrophy and muscularization of small distal pulmonary arteries. Although steady-state mRNA levels of prepro-ET-1 are not elevated in transgenic sl/sl as compared to wild-type lungs, ECE-1 mRNA is higher, thus contributing to the increase in circulating ET-1 [98] . In ET B R-deficient rats the pulmonary vessels show diminished endothelial NO synthase (eNOS) and NO production, supporting a role of NO in ET B R-mediated vasodilation in the pulmonary vasculature. Other studies in hypoxic pulmonary hypertensive rats have shown a decrease in PGI 2 synthase and PGI 2 production in ET B R-deficient rat lung [98] . These findings suggest that ET B R may provide a protective role and attenuate PH during chronic hypoxia. Also, in a rat model of monocrotalineinduced PH, an intravenous single bolus injection of ET-1 (1000 pmol/kg) caused a transient decrease in right ventricular systolic pressure (which is equal to the pulmonary arterial pressure) likely due to activation of endothelial ET B R, and this effect was not observed in control rats. In rats pretreated with the ET A R antagonist BMS-193884, ET-1 decreased right ventricular systolic pressure to a greater extent in monocrotaline-induced PH rats than in controls, likely due to greater activation of vasodilator ET B R in ECs of the pulmonary circulation. Pretreatment with the dual ET A R/ET B R antagonist SB-209670, abolished ETinduced decrease in right ventricular systolic pressure in both groups. It was concluded that ET A R antagonist may be more beneficial in the monocrotaline model of PH as it spares the enhanced activation of vasodilator ET B R in ECs [99] . This is supported by the observation that ET B R deficiency accelerates the progression of PH and neointimal lesions in monocrotaline-treated rats [98] . Also, pulmonary arterial ET-1 levels are 8-fold higher in the lungs of ET B R-deficient than wild-type rats [98] . Interestingly, in ET B R-deficient rats, ET A R-induced vascular contraction is reduced despite elevated plasma ET-1 and increased ET A R expression, suggesting uncoupling of ET A R expression from functional activity [100] . In dihydromonocrotaline-treated dogs, the ET A R antagonist FR139317 reduces both systemic and pulmonary vascular resistance, while the ET B R antagonist RES-7011 increases pulmonary arterial pressure [101] . Other studies have shown the emergence of ET B Rmediated vasoconstriction and ET B Rs in pulmonary VSMCs of fetal lambs with experimental congenital heart disease and increased pulmonary blood flow [102] .
Although ET receptor antagonists have not been very effective in systemic vascular disease, they appear to be more efficacious in PAH, and the differences in their efficacy have been partly related to their ability to alter VSMC migration [103] . It was found that ET-1 potently induced migration of pulmonary VSMCs that was inhibited by selective ET A R antagonist or combined ET A R/ET B R antagonist, but not by a selective ET B R antagonist, whereas ET-1 had minimal effect on migration of aortic VSMCs. The ET-1 induced pulmonary VSMC migration appeared to involve activation and phosphorylation of ERK 1/2 MAPK pathway and was less apparent in aortic VSMCs [103] .
In addition to modulators of the NO and PGI 2 pathway, ET receptor antagonists have been shown in randomized controlled clinical trials to confer improvements in functional status, pulmonary hemodynamics, and even slow the progression of PAH [104] . The ET A R antagonist ambrisentan at a dose of 5 to 10 mg daily and the combined ET A R/ET B R antagonist bosentan at a dose of 125 mg b.i.d have been approved for treatment of PAH in patients with a World Health Organization (WHO) functional class II to IV symptoms to improve exercise capacity and delay clinical worsening [105] . Combined ET A R/ET B R antagonists and selective ET A R antagonists may also improve the hemodynamics in PAH patients with chronic heart failure (CHF) [106] . The ET antagonist lowering effects of pulmonary arterial pressure may be modest in the short-term, but could have significant long-term benefits. For example, in PAH, ambrisentan causes relatively small improvement in the short-term, but such improvement could be meaningful as one-year survival is improved [106] . Some small clinical trials have shown beneficial effects of bosentan (500 ng -1g, b.i.d for 2 weeks on the hemodynamics, CHF and PAH [107] . However, the REACH-1 and ENABLE studies demonstrated that initiation of bosentan therapy 125 to 500 mg b.i.d is associated with increased risk of worsening CHF [108] . Also, the RITZ-1 to -5 and VERITAS studies tested the effects of tezosentan 25 to 100 mg/hr for 24 hr in improving acute heart failure as measured by changes in dyspnea, oxygen saturation and cardiac index, but no benefits were observed [109] .
Although both selective ET A R and dual ET A R/ET B R antagonists could be beneficial in PAH, it is difficult to ascertain whether these agents provide equivalent ET A R antagonism, or whether ET B R blockade provides additional benefit. Because VSM ET B R may contribute to the detrimental effects of ET-1 in PAH, complete blockade of the vasoconstrictive, proliferative and profibrotic effects of ET-1 by blocking both ET A R and ET B R may confer more benefits. However, these benefits may be offset by the loss of the protective role of endothelial ET B R. Although most dual ET A R/ET B R antagonists show greater affinity toward ET A R than ET B R [110] , they may block endothelial ET B R mediated vasodilator effects. Also, while selective ET A R antagonists are 100-fold more selective for ET A R than ET B R, higher doses of ET A R antagonist may block ET B R [110] , and thereby suppress endothelial ET B R-mediated vasodilation and impair ET B R induced ET-1 clearance. Larger clinical trials are needed to determine the short-term and long term benefits of ET receptor antagonists in PAH and CHF.
ET B R in Coronary Circulation and Dysregulation in Coronary Artery Disease
ET-1 is an important regulator of the coronary circulation. In the rat perfused heart, administration of ET-1 at low doses causes a reduction in coronary perfusion pressure, whereas at higher doses ET-1 causes a rise in coronary perfusion pressure [111] . Similarly, in anesthetized dogs, intracoronary bolus injection of lower doses (0.1 or 0.3 μg) of S6c caused a transient decrease in coronary resistance, likely via activation of endothelial ET B R, whereas higher doses (1 and 3 μg) caused a decrease in coronary diameter and blood flow likely via VSM ET B R [112] . In vitro experiments suggest that ET A R rather than ET B R plays a more prominent role in coronary vasoconstriction [113] [114] . In human coronary artery, ET-1 induced vasoconstriction is inhibited by the ET A R antagonist BQ123 but not the ET B R antagonist BQ788, supporting that ET-1 induced vasoconstriction is mainly through activation of ET A R [114] . Also, immunoblots and immunofluorescence staining revealed that ET A R expression is more predominant in the human coronary microvasculature, and ET B R seems to be less abundant, supporting a greater role for ET A R activation in coronary vasoconstrictor [114] . Also, in coronary arteries isolated from young and healthy pigs, ET-1 causes greater constriction than the ET B R agonist IRL-1620. BQ788, endothelium removal or L-NAME potentiates the constrictor response to ET-1 and IRL-1620, suggesting ET B Rmediated release of NO [115] .
However, in clinical and experimental ischemic heart disease, VSM ET B R appears to be upregulated in the coronary arteries and may play a role in promoting vasoconstriction [113] . VSM ET B R is upregulated in coronary arteries after organ culture, a technique used to mimic the conditions of the coronary arteries in ischemic heart disease [116] . In rat coronary artery, S6c normally induces a small vasoconstrictor response, but after organ culture for 24 hr, S6c induces strong vasoconstriction, indicating the presence of contractile ET B R [117] . Similar response to S6c after organ culture has been observed in porcine coronary artery [47] . The strong contractile effect of S6c in blood vessels in organ culture may be related to upregulation of contractile ET B R in VSMCs and/or loss of functional endothelium and its vasodilatory ET B R. ET B R mRNA and protein levels are enhanced in rat coronary arteries following organ culture [117] , and upregulation of contractile ET B R is inhibited by actinomycin D and cycloheximide, supporting a role of transcription and translation of ET B R, respectively. Coronary arteries in organ culture upregulate vasoconstrictor ET B R via transcriptional mechanisms and MEK-ERK 1/2 signaling [116] . Minimally modified low density lipoprotein (LDL), a risk factor of CAD, also upregulates ET B R in rat coronary VSMCs, mainly via activation of the ERK 1/2 MAPK and the downstream transcriptional factor NF-κB [118] .
ET-1 is upregulated in patients with CAD. Intravenous administration of bosentan in patients with stable CAD decreased BP and increased coronary diameter particularly in segments with mild angiographic changes, and the coronary vasodilator effects of bosentan were inversely related to plasma LDL cholesterol levels [119] . Also, patients with ischemic heart disease have elevated plasma levels of ET-1 and AngII and upregulation of ET B R and AT 1 R in subcutaneous arteries when compared with healthy controls [120] , suggesting that VSM ET B R may play a role in the pathology of CAD and could provide a target for pharmacological intervention. The observations that ET-1 induces coronary vasoconstriction and that VSM ET B R constrictor response is enhanced in the coronary vasculature during clinical and experimental ischemic heart disease suggest that mixed ET A R/ET B R antagonists could be more beneficial than selective ET A R antagonists.
ET B R in Cerebral Circulation and Dysregulation in Cerebral Ischemia
ET B R plays an important role in the cerebral circulation. In intact rat cerebral artery treated with the ET A R antagonist FR139317, intraluminal administration of S6c causes concentration-dependent vasodilation, suggesting a role of endothelial ET B R in cerebral vasodilation [121] . Also, in freshly isolated rat middle cerebral arteries, ET-1 elicits a strong contraction that is almost totally dependent on ET A R, while S6c shows no or weak contractile effect [122] . However, during cerebral ischemia there appears to be a switch from vasodilator endothelial ET B R to the vasoconstrictor VSM ET B R. For instance, ET B R is upregulated in human cerebral arteries in organ culture particularly under conditions that mimic those observed in cerebral ischemia [123] . Also, in rat cerebral arteries in organ culture for 24 to 48 hr, S6c causes upregulation of VSM ET B R and produces a strong contraction [122] . Similarly, in rat cerebral arteries cultured for 24 hr treatment with tumor necrosis factor-α or epidermal growth factor potentiates S6c-induced contraction, suggesting that cytokines and growth factors can enhance the expression of VSM ET B R in cerebral arteries and perhaps during cerebral ischemia [124] . Interestingly, minimally modified LDL, a risk factor for cerebral vascular disease, also upregulates VSM ET B R in rat basilar artery [125] . The upregulation of ET B R in cerebral VSMCs in organ culture may involve activation of PKC, CAMK-II, B-Raf/MEK/ERK 1/2 MAPK and NF-κB [125] .
Endothelial ET B R may also confer neuroprotective effects in cerebral ischemia. In a rat model of focal cerebral ischemia induced by middle cerebral artery occlusion, treatment with IRL-1620 improves neurological and motor function and reduces oxidative stress and infarct volume, suggesting that endothelial ET B R activation may be a therapeutic target for the treatment of focal cerebral ischemia and stroke [126] . Cerebral vasospasm develops in 30-70% of patients suffering from subarachnoid hemorrhage, leading to delayed cerebral ischemia, permanent neurological dysfunction and death. Cerebral vasospasm is associated with elevated ET-1 levels in the cerebrospinal fluid, implicating ET-1 as one of the factors in the pathogenesis of cerebral ischemia [127] . Studies have shown that the selective ET A R antagonist clazosentan reduces vasospasm in a Phase 2a blinded, placebo-controlled trial in patients with subarachnoid hemorrhage [127] . However, it remains uncertain as to whether clazosentan improves morbidity and mortality as these endpoints were not measured. Also, given that the contractile VSM ET B R could be upregulated during cerebral ischemia, the potential effects of dual ET A R/ET B R antagonists in the setting of subarachnoid hemorrhage may need to be examined.
Dysregulation of ET B R in Vascular Inflammation and Atherosclerosis
ET B R may play a role in conditions associated with vascular inflammation and atherosclerosis. Competitive binding studies in vitro revealed that ET B R are upregulated in coronary arteries from patients with atherosclerosis [128] . Also, accumulation of foamy macrophages and T-lymphocytes in human atherosclerotic lesions may cause a switch from ET A R to ET B R in VSMCs, suggesting that ET B R may play a more important role during the progression of atherosclerosis [129] . Studies have compared the effects of infusing ET-1 and S6c into the brachial artery while forearm blood flow (FBF) is measured in patients with atherosclerosis and healthy control subjects. ET-1 induced a vasoconstriction response that was similar in the two groups. In comparison, S6c evoked an initial vasodilation and increase in FBF that did not differ between the two groups, followed by vasoconstriction and reduction in FBF that were greater in the atherosclerotic patients than in controls, and correlated with LDL cholesterol levels, suggesting upregulation of VSM ET B R in atherosclerosis [130] . Intra-arterial infusion of the ET B R antagonist BQ788 evoked an increase in FBF in patients with atherosclerosis, but a 9% reduction in control subjects. BQ123+BQ788 evoked an increase in FBF in the patients but not control subjects. The increase in FBF evoked by selective ET A R blockade was less than that evoked by combined ET A R/ET B R blockade in atherosclerotic patients, suggesting an enhanced ET-1 mediated vascular tone, at least in part due to increased ET B R-mediated vasoconstriction [131] . In vitro and in vivo studies in mice have also demonstrated a shift from ET A R to ET B R in arteriosclerotic vessels [132] .
Studies have examined coronary tone and endothelial function before and after infusion of ET antagonists into unobstructed coronary arteries of patients with coronary atherosclerosis. BQ788 did not affect epicardial diameter but constricted the microcirculation, increased coronary sinus ET-1, and reduced NO levels likely due to reduced ET B R-mediated ET-1 clearance and NO availability. BQ123+BQ788 dilated epicardial and resistance arteries and improved endothelial dysfunction of epicardial arteries. It was concluded that ET-1 via ET A R contributes to basal constrictor tone and endothelial dysfunction, while ET B R mediates vasodilation in human coronary arteries with atherosclerosis [133] . ET A R blockade reduces atheroma plaque formation in apolipoprotein E-deficient mice [4] . Also, ET B R may mediate favorable inhibition of vascular remodeling after injury as supported by exaggerated injury in ET B R KO mice [134] . These observations suggest that selective ET A R antagonists may have greater therapeutic potential than nonselective agents in conditions associated with vascular inflammation and atherosclerosis [133] .
ET B R, Sex Differences, Pregnancy, and Early-Life programming
ET B R may be modulated differently between sexes. Studies have shown sex difference in the development of salt-sensitive superoxide-dependent HTN in ET B R-deficient rats, with females having greater increases in BP and plasma ET-1 levels in response to HS diet than males [135] . Also, in the rat model of carotid artery balloon injury and neointima formation, the neointima/media ratio is lower in females than males, and the sex difference is attenuated by ovariectomy and restored by treatment with 17β-estradiol. In ET B R-deficient rats, the neointima/media ratio increased to the same level in both male and female rats, and this increase was not affected by ovariectomy or 17β-estradiol treatment. Treatment with A-192621, a selective ET B R antagonist, abolished the sex difference in balloon injuryinduced neointima formation. These findings indicate that the sex differences in balloon injury-induced neointimal formation is abolished by genetic ET B R deficiency or its pharmacological blockade [136] . Thus sex steroids may modulate the vascular ET B R, and such effects may play a role in the sex differences in vascular function and the vascular changes associated with menopause.
ET B R may also play an important role during pregnancy. The ET A R antagonist A-127722 or FR-139317 lowers BP in both pregnant and nonpregnant rats, whereas the ET B R antagonist A-192621 causes HTN in pregnant rats, supporting a role of ET B R in modulating BP during pregnancy [137] . Also, relaxin may upregulate endothelial ET B R during pregnancy [138] . Preeclampsia is a pregnancy-associated disorder characterized by HTN, proteinuria and endothelial dysfunction. Placental ischemia/hypoxia could lead to increased synthesis and release of ET-1 in preeclampsia [139] . Plasma ET-1 levels are 2-to 3-fold higher in preeclamptic than normal pregnant women, and are highest during the late stages of the disease, suggesting a role of ET-1 in the progression into the malignant phase of preeclampsia rather than the initiation of the disease. The role of vascular ET A R and ET B R during pregnancy, and the potential effects of ET A R/ET B R antagonists in preeclampsia need to be further examined.
Early life stress may downregulate ET B R expression and increase acute stress-mediated BP in adult rats. In male wild-type and ET B R-deficient rats subjected to early life stress by maternal separation for 3 hr/day from day 2 to 14 of postnatal life, acute air jet stress caused elevation of BP, plasma corticosterone and plasma ET-1 levels in adult maternally separated rats compared with control non-handled littermates. Maternal separation and early life stress also caused downregulation of ET A Rs and ET B Rs in aortic tissue compared with control rats, which could lead to alterations in the ET pathway, and an exaggerated acute pressor response to stress in adulthood [140] .
Conclusions and Future Directions
In addition to ET A R, ET B R is important for the control of vascular reactivity and BP. The unique anatomical location of endothelial ET B R favors both the release of endotheliumderived vasodilators, which counteract the protracted vasoconstrictor effects of ET-1/ET A R, and clearance of ET-1 from the circulation. ET B Rs are also present in VSM and share several intracellular signaling pathways with the ET A R. The availability of selective ET B R agonists and antagonists and the development of transgenic ET B R-deficient animals have contributed to our understanding of the role of ET B R in the control of vascular function, and the changes in its role in pathological conditions and CVD. Clinical evidence supports vascular benefits of ET antagonists in treatment of PAH, and potential benefits in atherosclerosis, CHF, and renal failure. However, there is still a debate as to the benefits of ET A R antagonists alone vs. mixed ET A R/ET B R antagonists in CVD. Dual ET A R/ET B R antagonists such as bosentan, enrazaten and tezosentan may be beneficial in CHF and PAH. However, recent reports favor the use of selective ET A R antagonists over dual ET A R/ET B R antagonists [38] . Combined ET A R antagonist with ET B R agonist may need to be evaluated in conditions associated with decreased endothelial ET B R expression/activity. Targeting ECE-1 may also provide a new approach to alter the production of ET-1 in CVD.
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